Hematology

The drug also received orphan drug designation.

Many people are unaware that acute myeloid leukemia (AML) is the leading cause of acute leukemia in adults.

Two recently approved leukemia drugs could be enlisted against treatment-resistant lung cancer.

CAR NK cells are allogenic, which is defined as taking the cells from a non-related healthy donor rather than the patient themselves. Therefore, CAR NK cells have the potential to be manufactured in advance and stored for off-the-shelf immediate use.

Research may help to develop usable hematopoietic stem cells that could regrow a patient with leukemia’s blood system after chemotherapy and irradiation.

Valoctocogene roxaparvovec (Valrox, BioMarin Pharmaceutical Inc) would be the first gene therapy in the United States for the most common form of hemophilia if approved by the FDA.1

Belantamab mafodotin has the potential for durable responses in patients with multiple myeloma whose disease has relapsed or is resistant to standard therapies.

Patricia Spears discusses what clinical trials can offer and when to start discussing them with patients. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.

Immunotherapy drug blinatumomab showed benefit in pediatric patients with relapsed acute lymphoblastic leukemia who have minimal residual disease following chemotherapy.

A combination therapy of carfilzomib, dexamethasone, and daratumumab extended progression-free survival when compared with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

An oral formulation of azacitidine improved overall survival in patients with acute myeloid leukemia in first remission.

The current observational, longitudinal study focused on patient-reported outcomes on functioning, symptoms, and quality of life in patients with chronic lymphocytic leukemia.

A poster presented at the American Society of Hematology Annual Meeting and Exposition assessed disease-related health care utilization and costs among patients with multiple myeloma.

In a session at the American Society of Hematology Annual Meeting and Exposition, held December 7-10 in Orlando, Florida, experts presented on the evolution of CLL therapy, how to make treatment decisions, and what’s to come in the future based on ongoing studies.

Jennifer Woyach, MD, associate professor at The Ohio State University, gives an overview of the new data in chronic lymphocytic leukemia being presented at the 2019 American Society of Hematology Annual Meeting and Exposition.

Jennifer Woyach, MD, associate professor at The Ohio State University, discusses current clinical trials going on in the chronic lymphocytic leukemia space that are most likely to impact the treatment landscape.

Jennifer Woyach, MD, associate professor at The Ohio State University, explains how patient-specific factors can help determine treatment decisions in chronic lymphocytic leukemia.

The study evaluated lymphoma characteristics and outcomes in hepatitis C virus-associated B-cell non-Hodgkin lymphoma in African American patients.

A novel, off-the-shelf bispecific antibody could serve as a new treatment option for patients with non-Hodgkin lymphoma who don’t respond to CAR T-cell therapy.

A study looked at adherence rates and potential predictors of nonadherence in patients with hemophilia receiving emicizumab.

A prospective analysis of the CLL14 trial showed that fixed-duration treatment of venetoclax plus obinutuzumab achieved high rates of undetectable minimal residual disease.

Patients receiving novel oral therapeutics often have a high dependence on financial assistance; specialty pharmacies may help facilitate access to these therapies.

Pharmacy Times® will be on site at the 61st American Society of Hematology Annual Meeting and Exposition.

Researchers showed that treating multiple myeloma cells with gamma-secretase inhibitors allowed CAR T-cells to more accurately treat cancer tumors.

Top news of the day from across the health care landscape.